Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial.
Martin VossKatharina Johanna WengerNina von MettenheimJörg BojungaManuela VetterBianca DiehlKea FranzRuediger GerlachMichael W RonellenfitschPatrick N HarterElke HattingenJoachim P SteinbachClaus RödelJohannes RiegerPublished in: European journal of nutrition (2021)
The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
Keyphrases
- weight loss
- end stage renal disease
- physical activity
- study protocol
- clinical trial
- phase iii
- ejection fraction
- blood glucose
- newly diagnosed
- chronic kidney disease
- phase ii
- peritoneal dialysis
- papillary thyroid
- white matter
- randomized controlled trial
- squamous cell carcinoma
- insulin resistance
- blood pressure
- patient reported outcomes
- squamous cell
- metabolic syndrome
- adipose tissue
- skeletal muscle
- brain injury